Short Interest in Sanofi (NASDAQ:SNY) Decreases By 16.9%

Sanofi (NASDAQ:SNY) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 3,240,000 shares, a decrease of 16.9% from the March 31st total of 3,900,000 shares. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is currently 1.6 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Rise Advisors LLC increased its position in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new position in shares of Sanofi during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC increased its position in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth approximately $28,000. Finally, Register Financial Advisors LLC acquired a new position in shares of Sanofi during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SNY. TheStreet cut Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Stock Up 0.5 %

NASDAQ SNY traded up $0.27 during trading on Monday, hitting $49.40. The stock had a trading volume of 1,676,194 shares, compared to its average volume of 1,991,082. The company has a market capitalization of $124.96 billion, a PE ratio of 24.69, a P/E/G ratio of 1.48 and a beta of 0.61. The company’s 50-day moving average price is $47.71 and its two-hundred day moving average price is $48.32. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.93.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. As a group, sell-side analysts forecast that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.